

30th April 2026

Head Office

500 North Bristol Park
Northway
Filton
Bristol
BS34 7QH

Tel: 0117 921 7200

Fax: 0117 921 7201

Public Declaration

In April 2026, the NHS Cord Blood Bank, based at the above address, changed its technology for processing cord blood units for human application. Market scanning and a tender process failed to identify a suitably compliant solution.

The new technology is marketed in the United States as a Food & Drug Administration (FDA) approved medical device, however, in the EU and UK; the technology is marketed as 'for research use only'.

The technology was therefore adopted by the NHS Cord blood Bank under the UK Health Institution Exemption (HIE). The technology meets the essential requirements set out in Part II of the UK MDR 2002, Annex I, as modified by Schedule 2A.

The AXP II system is an automated, fully closed, sterile system that volume-reduces cord blood.

The system comprises of the following Class IIa components:

AXP II Device

XpressTRAK® software


AXP Processing bag sets

And the following Class I components:

AXP II docking station

QC bag sets

Cord blood is transferred from a standard collection bag to the processing set, which is placed in the AXP II device and centrifuged. After centrifugation the blood is stratified into red blood cell, buffy coat, and plasma segments. The AXP II device harvests each of these components into separate bags. The buffy coat becomes the cryopreserved product and is used for hematopoietic stem cell transplantation.



Kieran Herrity

Stem Cell Donation and Transplant Head of Accreditation, Compliance and Training

Kieran.Herrity@nhsbt.nhs.uk